For patients with moderate-to-severe prurigo nodularis, nemolizumab improves symptoms, according to a study published in the Oct. 26 issue of the New England Journal of Medicine. Shawn G. Kwatra, M.D.
Prurigo nodularis (PN) is extremely itchy skin that leads to a bumpy rash. The rash appears as the result of repeated scratching, picking, or rubbing of the itchy areas of the skin. There isn’t one ...
Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the ...
The FDA has granted nemolizumab Priority Review for the treatment of prurigo nodularis. The Food and Drug Administration (FDA) has accepted for review the Biologics License Applications (BLA) for ...
Please provide your email address to receive an email when new articles are posted on . By week 12, itch and pain scores decreased 78.3% and 53.7% in the prurigo nodular and chronic pruritus of ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SWX:GALD) today announced that full results from the phase III OLYMPIA 1 trial, a 24-week study which evaluated the efficacy and safety of nemolizumab ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Nemluvio (nemolizumab-ilto) to treat adults with prurigo nodularis. The approval was supported ...
Paris and Tarrytown, N.Y. September 28, 2022. The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult patients with prurigo nodularis. With this ...
About 75,000 adults in the U.S. living with prurigo nodularis are most in need of new treatment options. TARRYTOWN, N.Y. and PARIS, Sept. 28, 2022/ PRNewswire/-- Regeneron Pharmaceuticals, Inc. and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results